This is a working overview of prescription control, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-30 and is reviewed periodically as new material appears.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Combination therapy with creatine monohydrate, CoQ10, and lipoic acid was shown to improve "surrogate markers of cellular energy dysfunction" in some patients with different forms of mitochondrial cytopathies, including MELAS patients. The administration of L-arginine during acute stroke-like episodes has been shown to "[decrease] severity of stroke-like symptoms in MELAS, [enhance] dynamics of the microcirculation, and also [reduce] tissue injury from ischemia." High-dose taurine supplementation was used in a phase III clinical trial in which therapy was shown to "reduce the annual relapse rate of stroke-like episodes from 2.22 to 0.72". Taurine supplementation promotes resurgence of normal metabolic activity through the modulation of calcium homeostasis in dysfunctional mitochondria.
In other countries, such as Egypt, it is legal to use and purchase tobacco products regardless of age. Germany raised the purchase age from 16 to 18 on September 1, 2007. Some police departments in the United States occasionally send an underaged teenager into a store where cigarettes are sold, and have the teen attempt to purchase cigarettes, with their own or no ID. If the vendor then completes the sale, the store is issued a fine. Similar enforcement practices are regularly performed by Trading Standards officers in the UK, and by equivalents in Israel and the Republic of Ireland.
== Specific uses == Affinity chromatography can be used in a number of applications, including nucleic acid purification, protein purification from cell free extracts, and purification from blood. By using affinity chromatography, one can separate proteins that bind to a certain fragment from proteins that do not bind that specific fragment. Because this technique of purification relies on the biological properties of the protein needed, it is a useful technique and proteins can be purified many folds in one step.
=== Amino acid propensities === Large aromatic residues (tyrosine, phenylalanine, tryptophan) and β-branched amino acids (threonine, valine, isoleucine) are favored to be found in β-strands in the middle of β-sheets. Different types of residues (such as proline) are likely to be found in the edge strands in β-sheets, presumably to avoid the "edge-to-edge" association between proteins that might lead to aggregation and amyloid formation.
Myofascial pain syndrome (MPS), also known as chronic myofascial pain (CMP), is a syndrome characterized by chronic pain in multiple myofascial trigger points ("knots") and fascial (connective tissue) constrictions. It can appear in any body part. Symptoms of a myofascial trigger point include: focal point tenderness, reproduction of pain upon trigger point palpation, hardening of the muscle upon trigger point palpation, pseudo-weakness of the involved muscle, referred pain, and limited range of motion following approximately 5 seconds of sustained trigger point pressure. The cause is believed to be muscle tension or spasms within the affected musculature. However, emerging evidence suggests that fascial tissue and its biomechanical and neurophysiological properties may also contribute to the development and persistence of myofascial pain. Diagnosis is based on the symptoms and possible sleep studies. Treatment may include pain medication, physical therapy, mouth guards, and occasionally benzodiazepine. It is a relatively common cause of temporomandibular pain.
Sources: en.wikipedia.org
== External links == Galerie Loevenbruck (Levé's artistic representation): Photographs Archived 2 October 2011 at the Wayback Machine, biography Archived 2 October 2011 at the Wayback Machine, books Archived 2 October 2011 at the Wayback Machine, reviews and press Editions P.O.L. (Levé's publisher), including a video of the author reading from Œuvres Short essay on Levé's aesthetics, focusing particularly on Works Archived 13 August 2015 at the Wayback Machine Written works online: Excerpt from Lorin Stein's English translation of Autoportrait (Paris Review) Photo series Amérique Obituary notices: Libération, by Philippe Lançon, 17 October 2007; by Jacques Morice, Télérama, 22 October 2007 Adaptations/homages by other artists: Autoportrait(s) Archived 28 August 2012 at the Wayback Machine, an online graphic design tribute to Levé (Grand Prix ETPA 2010) by Anne Gardes; CQPVD, ou Ce que parler veut dire Archived 22 October 2013 at the Wayback Machine, a 2008 theatrical work by Jade Duviquet, adapted in part from Levé's Autoportrait
=== Computing === Hyperlink, from one electronic document to another link (Unix), a command-line program to link directory entries <link>, a type of HTML element Link, in a linked list Linker (computing), a program which converts object files to an executable Links (web browser) Microsoft Office Assistant Links, an animated cat Link layer in computer networking ln (Unix), a command-line program to create a link to a file Chainlink (blockchain), a cryptocurrency Link, an Internet wallet service from Stripe, Inc.
=== Secretion of Interleukin-10 === Genetically engineered L. lactis can secrete the cytokine interleukin-10 (IL-10) for the treatment of inflammatory bowel diseases (IBD), since IL-10 has a central role in downregulating inflammatory cascades and matrix metalloproteinases. A study by Lothar Steidler and Wolfgang Hans shows that in situ synthesis of IL-10 by genetically engineered L. lactis requires much lower doses than systemic treatments like antibodies to tumor necrosis factor (TNF) or recombinant IL-10. The authors propose two possible routes by which IL-10 can reach its therapeutic target. Genetically engineered L. lactis may produce murine IL-10 in the lumen, and the protein may diffuse to responsive cells in the epithelium or the lamina propria. Another route involves L. lactis being taken up by M cells because of its bacterial size and shape, and the major part of the effect may be due to recombinant IL-10 production in situ in intestinal lymphoid tissue. Both routes may involve paracellular transport mechanisms that are enhanced in inflammation. After transport, IL-10 may directly downregulate inflammation. In principle, this method may be useful for intestinal delivery of other protein therapeutics that are unstable or difficult to produce in large quantities and an alternative to the systemic treatment of IBD.
These "de facto experiments investigating the physiology of stress as well as the substances that might alleviate exhaustion" were not unknown outside cycling. Thomas Hicks, an American born in England on 7 January 1875, won the Olympic marathon in 1904. He crossed the line behind a fellow American Fred Lorz, who had been transported for 11 miles of the course by his trainer, leading to his disqualification. However, Hicks's trainer Charles Lucas, pulled out a syringe and came to his aid as his runner began to struggle.
Sources: en.wikipedia.org
Committee on Herbal Medicinal Products (HMPC) (22 May 2012). "Assessment report on Citrus bergamia Risso et Poiteau, aetheroleum Final" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 8 April 2014. Retrieved 7 April 2014. Committee on Herbal Medicinal Products (HMPC) (22 May 2012). "List of references supporting the assessment of Citrus bergamia Risso et Poiteau, aetheroleum Final" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 8 April 2014. Retrieved 7 April 2014.
Bird collections are curated repositories of scientific specimens consisting of birds and their parts. They are a research resource for ornithology, the science of birds, and for other scientific disciplines in which information about birds is useful. These collections are archives of avian diversity and serve the diverse needs of scientific researchers, artists, and educators. Collections may include a variety of preparation types emphasizing preservation of feathers, skeletons, soft tissues, or (increasingly) some combination thereof. Modern collections range in size from small teaching collections, such as one might find at a nature reserve visitor center or small college, to large research collections of the world's major natural history museums, the largest of which contain hundreds of thousands of specimens. Bird collections function much like libraries, with specimens arranged in drawers and cabinets in taxonomic order, curated by scientists who oversee the maintenance, use, and growth of collections and make them available for study through visits or loans.
==== CamAPS FX ==== CamAPS FX, a product of CamDiab Ltd, is a mobile app designed for individuals with type 1 diabetes. It operates in conjunction with various insulin pumps, including the mylife YpsoPump, DANA Diabecare RS, and DANA-i insulin pumps, and is compatible with continuous glucose monitoring systems such as the Dexcom G6 and Abbott FreeStyle Libre 3. The system utilizes a self-learning algorithm that adapts insulin delivery based on glucose data, adjusting every 8–12 minutes, and it is approved for use in individuals aged one year and older, with age requirements varying depending on the CGM system used. CamAPS FX is controlled via a smartphone app, currently available for Android devices, with iOS support in development. The app allows users to set personalized glucose targets and offers features like "Ease-off" and "Boost" modes to adjust insulin needs, as well as a "Slowly absorbed meal" function for managing the effects of high-fat or low-glycemic meals. Remote monitoring capabilities are included through app-based sharing and SMS alerts. The system’s algorithm, developed at the University of Cambridge, has been validated in multiple clinical trials, showing consistent improvements in glycemic control and quality of life.
Listeria monocytogenes, some species of Rickettsia, Shigella flexneri and other intracellular germs escape from phagocytic vacuoles by coating themselves with a capsule of actin filaments. L. monocytogenes and S. flexneri both generate a tail in the form of a "comet tail" that gives them mobility. Each species exhibits small differences in the molecular polymerization mechanism of their "comet tails". Different displacement velocities have been observed, for example, with Listeria and Shigella found to be the fastest. Many experiments have demonstrated this mechanism in vitro. This indicates that the bacteria are not using a myosin-like protein motor, and it appears that their propulsion is acquired from the pressure exerted by the polymerization that takes place near to the microorganism's cell wall. The bacteria have previously been surrounded by ABPs from the host, and as a minimum the covering contains Arp2/3 complex, Ena/VASP proteins, cofilin, a buffering protein and nucleation promoters, such as vinculin complex. Through these movements they form protrusions that reach the neighbouring cells, infecting them as well so that the immune system can only fight the infection through cell immunity. The movement could be caused by the modification of the curve and debranching of the filaments. Other species, such as Mycobacterium marinum and Burkholderia pseudomallei, are also capable of localized polymerization of cellular actin to aid their movement through a mechanism that is centered on the Arp2/3 complex.
The mechanism by which minoxidil promotes hair growth is not fully understood. Minoxidil is an adenosine 5'-triphosphate (ATP)-sensitive potassium channel opener, causing hyperpolarization of cell membranes. Theoretically, by widening blood vessels and opening potassium channels, it allows more oxygen, blood, and nutrients to the follicles. Moreover, minoxidil contains a nitric oxide moiety and may act as a nitric oxide agonist. This may cause follicles in the telogen phase to shed, which are then replaced by thicker hairs in a new anagen phase. Minoxidil is a prodrug that is converted by sulfation via the sulfotransferase enzyme SULT1A1 to its active form, minoxidil sulfate. The effect of minoxidil is mediated by adenosine, which triggers intracellular signal transduction via both adenosine A1 receptors and two sub-types of adenosine A2 receptors (A2A and A2B receptors). Minoxidil acts as an activator of the Kir6/SUR2 channel upon selective binding to SUR2. The expression of SUR2B in dermal papilla cells might play a role in the production of adenosine. Minoxidil induces cell growth factors such as VEGF, HGF, IGF-1 and potentiates HGF and IGF-1 actions by the activation of uncoupled sulfonylurea receptor on the plasma membrane of dermal papilla cells. A number of in vitro effects of minoxidil have been described in monocultures of various skin and hair follicle cell types including stimulation of cell proliferation, inhibition of collagen synthesis, and stimulation of vascular endothelial growth factor, prostaglandin synthesis and leukotriene B4 expression.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.